

CONSUMER VNR TRANSCRIPT

EMBARGOED: 12:01AM AEST, THURSDAY, MARCH 20, 2025

Please click on link to watch vision vimeo.com/1065700390/f866c703d3?share=copy

Current run time: 23:39

QBiotics Group celebrating 25 years of harnessing Queensland's natural environment at the World Science Festival Brisbane (WSFB)

Dr. Victoria Gordon

Co-Founder & Non-Executive Director, QBiotics Group, **BRISBANE**

(00:16 – 00:26) Self-introduction

I'm Dr. Victoria Gordon. I'm Co-Founder and currently Non-Executive Director of the QBiotics Group.

(00:26 - 00:45)

When and by whom was the original company of the QBiotics Group founded?

The original company of the QBiotics Group was called EcoBiotics. And EcoBiotics was founded by myself and Dr. Paul Reddell. We're former CSIRO research scientists that was founded in 2000.



(00:45 - 00:57)

What was the unique discovery technology that formed the basis of Ecobiotics?

And the basis of EcoBiotics was the discovery technology that we developed called EcoLogic. It was quite a unique discovery technology.

(00:57 - 01:35)

Can you describe your discovery platform, EcoLogic?

Paul Reddell and I saw an opportunity to refine the search for small biologically active molecules from the natural environment. We put out the, the information that we have on how the natural environment functions, particularly plants. They produce this particular chemicals to repel, to attract, to access nutrients. We understand how the natural system works. And so we put together targeted strategies for particular biological activity and, and we called that Ecologic. That's our discovery platform.

(01:35 - 02:05)

How was the QBiotics Group formed?

EcoBiotics was the first company, and we functioned as a discovery company until about 2010, when we decided to take one of our discoveries and develop it into the clinic. And to do that, we established a company called QBiotics, and we put a development group into QBiotics. And then in 2017, we merged those two companies to form the QBiotics Group.

(02:05 - 02:39)

What compelled you to establish the QBiotics Group?

Both Paul and I, uh, we, we worked with nature in CSIRO and the extraordinary biological activity that is out there in the natural environment, of course, plants defending themselves and producing chemicals to survive. And so we saw an opportunity to really refine the approach and the, and, and target plant material for bi, the biological specific biological activity. And that really converts to particular medicines.

(02:39 - 03:04)

What has the QBiotics Group discovered to date using the EcoLogicTM platform?

The first of our programmes is in cancer. We have tigilanol tiglate, which is an anti-cancer drug that really is active against a broad range of solid tumours. The second of our programmes is in wound healing. We have a wound healing product that is active against chronic and acute wounds and burns, and we have two earlier programmes in antibiotics and anti-inflammatories.

(03:04 - 03:25)

What has the QBiotics Group discovered with EBC-1013 & wound healing?

A second programme in QBiotics is in wound healing. It's a small molecule called EBC-1013, and it is a pharmaceutical, not a device, a simple gel, and it's active against chronic wounds, acute wounds and burns, the whole range of wounds.

(03:25 - 04:10)

How does tigilanol tiglate destroy solid tumours?

Tigilanol tiglate is a very simple drug to use. You inject it directly into the tumour, and initially there's a, an, an action against the tumour cells themselves, they basically, they break down the secondary responses against the tumour vasculature. The drug makes the tumour vasculature break down, and this whole response is a, it results in total destruction of the tumour, and that occurs within five to 10 days. And of course, when we're treating external tumours, there is a wound or a pocket left. Of course, our drug also stimulates healing of that site, and that site heals mostly with minimum to no scarring.

(04:10 - 04:28)

How does tigilanol tiglate improve wound healing?

Our wound healing gel addresses all of the problems with the wound. It has an antimicrobial effect. It deals with the, the infill of the wound, and also it stimulates closure of the wound as well.

(04:28 - 04:59)

How is the QBiotics Group harnessing nature to help solve medical problems?

The natural environment is complex and particularly plants. Of course, you and I can actually run away from our enemies, but, but plants can't. And so, what they've done is, they've developed these extraordinary, elegant systems to defend themselves. And of course, most of that is chemical defence, and they're, they're solving their own problems with chemistry. And in many ways, they're solving our problems, our medical problems with that chemistry as well.

(04:59 - 05:20)

How does the QBiotics Group promote nature to ensure its preservation for future generations and ongoing discoveries?

The more successful QBiotics is in the discovery and development of medicines from nature, the greater the argument to preserve our natural environment, and this is not just in Australia, but worldwide.

(05:20 - 05:38)

What is soft tissue sarcoma, and why is it crucial to develop new treatment options for this disease?

Under the banner of soft tissue sarcomas is approximately 70 different tumour types. So this is a really complex disease. We still don't have the optimum solution for soft tissue sarcomas, and that's why we in QBiotics are concentrating on that disease.

(05:38 - 05:54)

How is your research in soft tissue sarcoma progressing?

We're demonstrating efficacy and good safety. And the, and the results I think are, are so impressive that we've been awarded, um, orphan drug designation by the FDA.

(05:54 - 06:16)

How is your head & neck cancer research progressing?

Head and neck cancer can be quite a debilitating disease because it is really, um, in the area of the face, et cetera. Our phase two, in our phase two studies, we're actually proving efficacy of our drug against head and neck cancer and also safety as well.

(06:16 - 06:34)

Why is 2025 so significant for the QBiotics Group?

This year, the QBiotics Group is 25 years old. We've, we weathered many storms. There's, we've dealt with many issues in the company, and we've survived, and we are here, we are growing, we are flourishing, and we're excited about the future.

(06:34 - 06:41)

How is the QBiotics Group celebrating its 25th anniversary this year?

The QBiotics Group is a programme partner for the Unseen Worlds Exhibition for the World Science Festival in Brisbane.

(06:41 - 06:52)

What will the QBiotics Group be showcasing at the World Science Festival Brisbane?

QBiotics, uh, will be proudly showcasing our anti-cancer drug, tigilanol tiglate with, with a range of photographs and microscopic images.

(06:52 - 07:22)

What do you consider to be the three greatest achievements of the QBiotics Group over the past 25 years?

I feel the three greatest achievements for the QBiotics Group is of course, primarily EcoLogic, our wonderful discovery technology; the drugs that we've actually sourced through EcoLogic - our anti-cancer drug, our wound healing drug, and other programmes. And of course, the extraordinary people that we've attracted to the company to work with us and collaborate with us to, in the development of these drugs.

(07:22 - 08:01)

What accomplishment at the QBiotics Group are you most proud of?

I'm mostly proud of the culture that we've actually developed in QBiotics. This is a culture that's based on ethics and, and on respect. We have respect for each other, for those who we collaborate with, our shareholders, but importantly, for the patients, the human and animal patients that we are developing our drugs for, and also the natural environment that we work in, and of course the animals in research. All of that comes together to, to really form a company, that I personally am very proud of.

(08:01 - 08:43)

Can you reflect on the role of your clinical advisory board?

We've been incredibly fortunate to attract global key opinion leaders in oncology to form our clinical advisory board. This is a, this is a group of people that advise us on the development of our anti-cancer drugs and also clinical advisory boards for our other programmes as well.

But these are people that really know what they're doing. They're out there in the clinic. They're actually in the, the real world, at the coal, at the coalface with patients. And they're actually helping us to develop a drug, that is not only going to be solving solutions, but easy to use, and it's just accessible.

(08:43 - 09:14)

What does the future hold for the QBiotics Group?

Paul Reddell and I, as founders of the QBiotics Group, are really building the company for the future. We are here to stay. We are building a biopharmaceutical company because in Ecologic we have this fantastic innovation, but of course, we can't do everything ourselves. And so we see QBiotics as the centre hub of a group of collaborative companies. And this is a, this is fantastic for Australia. We're building for the future.

(09:14 - 09:38)

What is your message to those who have supported the QBiotics Group over the past 25 years? Our shareholders are so important to QBiotics Group and without them, Paul Riddell and I would still be standing in the rainforest saying, we've got a great idea. So I'd really like to pass on our heartfelt thanks to all of these extraordinary people who've been so very patient and just continue to support us over many, many years.

OVERLAY

Dr Victoria Gordon	
10:21 – 10:31	Mid-shot of Dr Gordon walking in nature (from behind)
	Mid-shot of Dr Gordon walking in nature (front on)
10:31 - 10:48	Close-up of Dr Gordon walking in nature and inspecting leaves
10:48 – 11:16	Close-up of Dr Gordon walking in nature, looking up at plants and inspecting
11.17 11.04	leaves of tree
11:16 – 11:24	Extreme close-up of Dr Gordon walking in nature
11:24 - 11:42	Full shot of Dr Gordon walking towards camera in nature
11:42 – 12:01	Extreme close-up of Dr Gordon inspecting plants and looking up
12:01 – 12:07	Extreme close-up of Dr Gordon looking down to inspect plant
12:07 – 12:47	Extreme close-up of Dr Gordon's hands inspecting plant
12:47 – 13:11	Extreme close-up of Dr Gordon looking up inspecting plants
13:11 – 13:59	Full shot of Dr Gordon walking down path in nature and looking up to inspect
	plants
13:59 – 14:20	Extreme close-up of Dr Gordon looking up, camera panning right then left
14:20 – 14:47	Long shot of Dr Gordon walking away from camera into nature
14:47 – 15:12	Close-up of plant leaves, panning right
15:12 - 15:25	Close-up of plant leaves, panning left
15:25 – 16:37	Full to mid shot of Dr Gordon walking towards camera in nature
16:37 – 16:56	Extreme close-up of Dr Gordon's feet walking in nature
16:56 – 17:07	Medium close-up of Dr Victoria Gordon's legs walking in nature
17:07 – 18:21	Medium shot of Dr Gordon walking towards the camera, inspecting leaves
	and continuing to walk towards camera into a close-up shot
18:21 – 18:50	Extreme close-up of Dr Gordon's hands inspecting plant
18:50 - 19:25	Extreme long-shot of Dr Gordon walking towards camera in nature
19:25 - 19:52	Close-up of Pomeranian dog walking towards camera
19:52 - 20:02	Close-up of Dr Gordon holding Pomeranian
20:02 - 20:15	Mid-shot of Dr Gordon holding two dogs
20:15 - 20:22	Extreme close-up of Dr Gordon holding and petting Pomeranian
20:22 - 20:38	Mid shot of Dr Gordon sitting on bench with Pomeranian
20:38 - 20:43	Extreme close-up of Dr Gordon petting Poodle
20:43 - 20:54	Extreme close-up of Dr Gordon petting Pomeranian
Dr Paul Reddell	
20:54 - 20:55	Upwards shot of sky
20:55 - 21:01	Extreme wide shot of Daintree
21:01 - 21:02	Birds eye shot of Daintree
21:02 - 21:09	Zoom into Daintree
21:09 - 21:12	Wide shot of trees in Daintree
21:12 - 21:13	Wide shot of trees in Daintree
21:13 - 21:17	Mid shot of trees in Daintree

21:17 – 21:19	Mid-shot of trees in Daintree (looking up)
21:19 – 21:23	Close-up of tree branches
21:23 – 21:28	Panning up shot of tree branches
21:28 – 21:30	Panning (left) shot of tree branches
21:30 - 21:35	Panning out close-up shot of tree leaves
21:35 – 21:37	Panning up close-up shot of tree in Daintree
21:37 – 21:42	Close-up of leaves in trees
21:42 – 21:46	Panning forward shot of leaves in Daintree
21:46 - 21:47	Close-up of leaves growing out of trees in Daintree
21:47 - 21:49	Close-up of leaves growing out of tree in Daintree
21:49 - 21:53	Extreme close-up of leaves in Daintree
21:53 - 21:55	Extreme close-up of leaves growing out of tree
21:55 - 21:56	Extreme close-up of wet leaf in Daintree
21:56 - 22:06	Mid shot of Dr Redell walking through Daintree
22:06 - 22:10	Wide shot of Dr Redell walking through Daintree
22:10 - 22:11	Mid-shot of Dr Redell on pathway in the Daintree
21:11 - 22:19	Panning mid-shot from behind of Dr Redell looking at tree in Daintree
22:19 - 22:22	Mid shot of Dr Redell touching tree in Daintree
22:22 – 22:25	Close-up of Dr Redell looking at plants
22:25 - 22:35	Extreme close-up of Dr Redell holding and inspecting plants

ends#

For more information regarding this VNR, please contact:

Kirsten Bruce, Principal, VIVA! Communications

T 02 9968 3741 / 1604

M 0401 717 566

E <u>kirstenbruce@vivacommunications.com.au</u>